세계의 파머징 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Pharmerging Market is presumed to reach the market size of nearly USD 4.75 Billion by 2032 from USD 1.89 Billion in 2023 with a CAGR of 10.78% under the study period 2024-2032.

Pharmerging refers to countries experiencing rapid economic growth and development in their pharmaceutical and healthcare sectors, leading to emerging opportunities for pharmaceutical companies and healthcare providers. These countries typically have large populations, increasing healthcare spending, improving healthcare infrastructure, and rising demand for healthcare services and pharmaceutical products. These markets include countries such as Brazil, Russia, India, China, Mexico, Turkey, South Korea, and South Africa, among others. These markets offer attractive opportunities for pharmaceutical companies to expand their presence, introduce new products, and address unmet medical needs in diverse therapeutic areas.

MARKET DYNAMICS

Increasing urbanization and rising incomes in emerging economies lead to improved access to healthcare services, which drives demand for pharmaceutical products. This includes generic and branded drugs for various therapeutic areas, including chronic and infectious diseases. They are additionally expanding healthcare infrastructure and government initiatives to enhance healthcare access & affordability, further fueling pharmaceutical market growth in pharmerging countries. Moreover, the growing prevalence of lifestyle-related diseases and aging populations in these regions drives demand for pharmaceuticals, including innovative treatments and specialty drugs. Furthermore, rising investment in research and development (R&D) and innovation by domestic and multinational pharmaceutical companies in pharmerging markets contribute to market expansion. Favorable regulatory environments and intellectual property reforms in some pharmerging countries attract investment and foster innovation in the pharmaceutical industry, driving market growth and competition. However, changes in healthcare policies, regulatory frameworks, and economic conditions in emerging markets may challenge market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmerging. The growth and trends of Pharmerging industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmerging market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics), OTC Drugs)
• Healthcare (Medical Devices, Diagnostic Instruments, Others (IT and Record Management))

By Indication

• Lifestyle Diseases
• Cancer and Autoimmune Diseases
• Infectious Diseases
• Others

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• E-commerce
• Drugs Stores

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmerging market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmerging market include Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline Plc, Lupin, Tata Consultancy Services Ltd., Sun Pharmaceutical Industries Ltd., Huadong Medicine Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. PHARMERGING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMERGING MARKET ANALYSIS BY PRODUCT TYPE

• 5.1. Overview By Product Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Product Type
• 5.4. Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics), OTC Drugs) Historic and Forecast Sales By Regions
• 5.5. Healthcare (Medical Devices, Diagnostic Instruments, Others (IT and Record Management)) Historic and Forecast Sales By Regions

6. GLOBAL PHARMERGING MARKET ANALYSIS BY INDICATION

• 6.1. Overview By Indication
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Indication
• 6.4. Lifestyle Diseases Historic and Forecast Sales By Regions
• 6.5. Cancer and Autoimmune Diseases Historic and Forecast Sales By Regions
• 6.6. Infectious Diseases Historic and Forecast Sales By Regions
• 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL PHARMERGING MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Distribution Channel
• 7.4. Hospitals Historic and Forecast Sales By Regions
• 7.5. Clinics Historic and Forecast Sales By Regions
• 7.6. Retail Pharmacies Historic and Forecast Sales By Regions
• 7.7. E-commerce Historic and Forecast Sales By Regions
• 7.8. Drugs Stores Historic and Forecast Sales By Regions

8. GLOBAL PHARMERGING MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMERGING COMPANIES

• 9.1. Pharmerging Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF PHARMERGING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Abbott Laboratories
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Koninklijke Philips N.V.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. F. Hoffmann-La Roche Ltd.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Merck & Co. Inc.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Novartis AG
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Johnson & Johnson
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Teva Pharmaceutical Industries Ltd.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. AstraZeneca
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. GlaxoSmithKline Plc
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Lupin
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Tata Consultancy Services Ltd.
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Sun Pharmaceutical Industries Ltd.
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Huadong Medicine Co. Ltd
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies